David G Birch
David G Birch is an expert in Ophthalmology at University of Alabama (United States). As of October 2026, ScienceLeadR ranks David G Birch in the top 1% of experts worldwide for Retinitis, Retinal Diseases and Eye Diseases, Hereditary. David G Birch has authored 529 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 1 of them ongoing. SLR score: 1,390 (community average: 125). How the SLR is computed.
LeadR Profile
Ophthalmology
Subspecialties: Genetics - Psychology - Otolaryngology
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1987 - 2026
Number : 529
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Microperimetry Sensitivity Changes at the Functional Transition Zone and at the EZ Margins in X-Linked Retinitis Pigmentosa Treated With Gene Therapy. PMID 42847595 — eye, retinitis, genes, eye diseases, retinitis pigmentosa, therapeutics, retinaldehyde, genes, x-linked | Transl Vis Sci Technol | 2026 | 0 |
| Unlike Any Other Time: Moving Forward to Support Education, School Health, and Social Justice During Unprecedented Challenges. PMID 42841773 — schools, health education, social justice, education | J Sch Health | 2026 | 0 |
| A 48-Month, Prospective, Multicenter, Natural History Study of Choroideremia. PMID 42787486 — research design, choroideremia, natural history, visual fields, visual acuity, history | Ophthalmol Sci | 2026 | 0 |
| Phase I/IIa Study of an Intravitreal Optogenetic Therapy (AGN-151597) in Patients with Advanced Retinitis Pigmentosa. PMID 42602510 — eye, retinitis, genes, vision, ocular, safety, visual acuity, retinitis pigmentosa, therapeutics, retinal diseases, retinaldehyde, intraocular pressure, optogenetics | Ophthalmol Sci | 2026 | 0 |
| Lens Opacity in ABCA4-Associated Stargardt Disease Patients in the ProgStar Study. PMID 42484594 — eye, incidence, stargardt disease, ophthalmology, prevalence, risk factors, cataract | Invest Ophthalmol Vis Sci | 2026 | 0 |
Clinical Studies 11
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 5
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Oral N acetylcysteine for Retinitis Pigmentosa NCT05537220 — usher syndromes, retinitis, vision, ocular, retinal rod photoreceptor cells, safety, pharmaceutical preparations, acetylcysteine, stress, physiological, tablets, photoreceptor cells, antioxidants, visual acuity, retinitis pigmentosa, random allocation, mutation | Phase 3 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map